-
GPS-Linked Training Shirt Gives Data for Runners
A Spanish company has developed a training shirt fitted with sensors, Bluetooth transmitter, and GPS receiver to provide runners with real-time data on their performance and route, either in training or competition. The company, emxys, is a startup enterprise in Alicante, Spain, but also taking part in the European Space Agency’s (ESA’s) Business Incubation Centre…
-
Water Blade Technology Developed to Disable IEDs
A device developed at Sandia National Laboratory in Albuquerque, New Mexico shoots a blade of water capable of penetrating steel that helps American troops in Afghanistan disable deadly improvised explosive devices, or IEDs. Sandia licensed the technology to TEAM Technologies Inc., also in Albuquerque. The company made its first shipment of some 3,000 new water…
-
Academic, Industrial Researchers Enhance Nanospring Capabilities
Researchers at Oregon State University in Corvallis and University of Idaho in Moscow, with colleagues from GoNano Technologies also in Moscow, loaded biological molecules onto a type of nanostructure called “nanosprings” that are able to maximize surface area in chemical processes operating on a micrometer scale. The researchers found a way to attach enzymes to…
-
“Why are we copyrighting science?”
Two researchers in psychiatry from University of Colombo in Sri Lanka criticized the practice of copyrighting measurement scales, tests, and related technologies used in their field and other disciplines, saying that the practice hinders the advance of medical science. Varuni de Silva and Raveen Hanwella published their commentary, “Why are we copyrighting science?”, in this…
-
Genome Sequence Completed for Endangered Tasmanian Devil
Researchers from the Wellcome Trust Sanger Institute in Cambridge, U.K. and life science instrumentation company Illumina Inc. in San Diego, California have created a draft genome sequence for the endangered Tasmanian devil and will use these results to find genetic mutations in the transmissible cancer that is ravaging its population. The findings, say the Wellcome…
-
New York Life Sciences Landing More Venture, Government Funds
The New York Biotechnology Association (NYBA) in Stony Brook said today that in the first half of 2010, universities, companies and research organizations in New York State received $336.6 million in private and government investment. NYBA based its report on results from the quarterly PricewaterhouseCoopers Money Tree Report and data from the National Institutes of…
-
Energy Dept. Awards Grants for University Tech. Commercialization
The U.S. Department of Energy (DoE) selected five projects to build and strengthen what it calls “innovation ecosystems” designed to accelerate the movement of new energy technologies from university laboratories to the market. This is the first time DoE has funded this type of university-based commercialization. The ecosystems will bring together universities, the private sector,…
-
Startups License Academic Research to Combat Counterfeiting
Two startup companies completed exclusive license agreements with University of Arkansas – Little Rock (UALR) to bring to market technology developed by UALR’s Nanotechnology Center that offers anti-counterfeiting solutions for manufacturers. UALR says the technology will enable companies and government agencies to authenticate items with an invisible and unique code that is virtually impossible to…
-
University Licenses Carbon Nanotube Technology for Fuel Cells
Florida State University (FSU) in Tallahassee has commercialized research on nanomaterials by one of its engineering professors to a company making components for hydrogen fuel cells. Bing Energy Inc., a manufacturer of fuel cell components in Chino, California, has entered into an agreement with FSU that gives it exclusive use of Zheng’s patented technology. Jim…
-
Blood Disorder Gene Therapy Results Published
The current online issue of the journal Nature features an article with the first results of a clinical trial testing gene therapy on beta-thalassemia, an inherited blood disorder. The trial tests the drug LentiGlobin, developed by bluebird bio (formerly Genetix Pharmaceuticals Inc.) of Cambridge, Massachusetts. The Nature paper describes the experiences of the first patient…